JP2018522907A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522907A5
JP2018522907A5 JP2018506346A JP2018506346A JP2018522907A5 JP 2018522907 A5 JP2018522907 A5 JP 2018522907A5 JP 2018506346 A JP2018506346 A JP 2018506346A JP 2018506346 A JP2018506346 A JP 2018506346A JP 2018522907 A5 JP2018522907 A5 JP 2018522907A5
Authority
JP
Japan
Prior art keywords
seq
car
chimeric antigen
antigen receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018506346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522907A (ja
Filing date
Publication date
Priority claimed from PCT/EP2016/051467 external-priority patent/WO2016120216A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/067800 external-priority patent/WO2017025323A1/en
Publication of JP2018522907A publication Critical patent/JP2018522907A/ja
Publication of JP2018522907A5 publication Critical patent/JP2018522907A5/ja
Withdrawn legal-status Critical Current

Links

JP2018506346A 2015-08-11 2016-07-26 Cd38抗原を標的とするためおよびcd38遺伝子を不活化するために操作された、免疫療法用の細胞 Withdrawn JP2018522907A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201570518 2015-08-11
DKPA201570518 2015-08-11
EPPCT/EP2016/051467 2016-01-25
PCT/EP2016/051467 WO2016120216A1 (en) 2015-01-26 2016-01-25 mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
PCT/EP2016/067800 WO2017025323A1 (en) 2015-08-11 2016-07-26 Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation

Publications (2)

Publication Number Publication Date
JP2018522907A JP2018522907A (ja) 2018-08-16
JP2018522907A5 true JP2018522907A5 (cg-RX-API-DMAC7.html) 2019-07-25

Family

ID=53836344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506346A Withdrawn JP2018522907A (ja) 2015-08-11 2016-07-26 Cd38抗原を標的とするためおよびcd38遺伝子を不活化するために操作された、免疫療法用の細胞

Country Status (12)

Country Link
US (1) US10709775B2 (cg-RX-API-DMAC7.html)
EP (1) EP3334442B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018522907A (cg-RX-API-DMAC7.html)
KR (1) KR20180041152A (cg-RX-API-DMAC7.html)
CN (1) CN108495641A (cg-RX-API-DMAC7.html)
AU (1) AU2016307050A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018002600A2 (cg-RX-API-DMAC7.html)
CA (1) CA2994746A1 (cg-RX-API-DMAC7.html)
IL (1) IL257009A (cg-RX-API-DMAC7.html)
MX (1) MX2018001776A (cg-RX-API-DMAC7.html)
RU (1) RU2018107754A (cg-RX-API-DMAC7.html)
WO (1) WO2017025323A1 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CA2967222C (en) * 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
MA43134A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US10724043B2 (en) 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN109232742B (zh) * 2017-07-11 2021-10-22 深圳市第二人民医院 一种嵌合抗原受体及其应用
EP3654994B1 (en) * 2017-07-18 2022-12-28 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
KR20200076732A (ko) * 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
WO2019111249A1 (en) * 2017-12-05 2019-06-13 The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof
US12139522B2 (en) 2017-12-05 2024-11-12 The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center T-cells comprising two different chimeric antigen receptors and uses thereof
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
AU2019216269B2 (en) * 2018-01-30 2025-05-01 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
CN112041432A (zh) * 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
CN113395978A (zh) * 2018-07-11 2021-09-14 动量制药公司 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
KR20210044218A (ko) * 2018-07-11 2021-04-22 모멘타 파머슈티컬스 인코포레이티드 CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN109293774B (zh) * 2018-10-16 2021-05-28 南京医科大学 特异性结合cd19的全人源化抗体及应用
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
AU2019387377B2 (en) * 2018-11-30 2026-07-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD38 immunotherapy
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN111676195A (zh) * 2019-03-11 2020-09-18 北京卡替医疗技术有限公司 一种治疗t细胞肿瘤的ucar免疫细胞
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020220027A1 (en) * 2019-04-25 2020-10-29 Purdue Research Foundation Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
AU2020299774A1 (en) 2019-07-03 2022-01-20 Peptidream Inc. CD38-binding agents and uses thereof
WO2021009263A1 (en) * 2019-07-16 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技(成都)有限公司 药物组合物及其制备方法和应用
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス,インコーポレイテッド 小化合物を使用するiPSC由来エフェクター免疫細胞の増強
CN111909966B (zh) * 2020-04-01 2021-09-21 苏州克睿基因生物科技有限公司 一种制备经修饰的免疫细胞的方法
CN111484563B (zh) * 2020-04-30 2020-11-10 徐州医科大学附属医院 一种抗cd38嵌合抗原受体及其应用
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022056489A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
WO2023081200A2 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024052318A1 (en) * 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
WO2024054678A2 (en) * 2022-09-09 2024-03-14 Regents Of The University Of Minnesota Antibodies against fentanyl and analogs and methods of use thereof
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
JP2025074700A (ja) * 2023-10-30 2025-05-14 学校法人藤田学園 抗cd38-carを発現する細胞傷害性免疫担当細胞、その製造方法、および当該免疫担当細胞を含む医薬組成物
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
US20250262300A1 (en) * 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
TW202615096A (zh) * 2024-07-19 2026-04-16 國立大學法人京都大學 SARS-CoV-2感染症治療及/或預防用細胞及其製法
CN120349403B (zh) * 2025-04-23 2026-08-07 河南农业大学 一种抗猪流行性腹泻病毒n蛋白的单克隆抗体及其识别的抗原表位肽和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6704794A (en) 1993-04-13 1994-11-08 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6642043B1 (en) 1996-03-12 2003-11-04 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
CN1826408B (zh) 2003-03-14 2011-01-26 塞托·帕尔斯科技公司 大容量离体电穿孔法
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
EP2877488B1 (en) 2012-07-24 2021-02-24 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
CA2912375C (en) * 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
TR201910814T4 (tr) * 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
US20170296623A1 (en) * 2014-12-17 2017-10-19 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm

Similar Documents

Publication Publication Date Title
US20260115284A1 (en) Toxicity management for anti-tumor activity of cars
US12583904B2 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
AU2019222550B2 (en) Modified pluripotent stem cells and methods of making and use
EP1503794B9 (en) Methods of treatement using ctla-4 antibodies
RU2018107754A (ru) Клетки для иммунотерапии, созданные для таргетинга антигена cd38 и для инактивации гена cd38
US20190358262A1 (en) Methods for modulation of car-t cells
TWI807077B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
KR20210149049A (ko) T 세포 수용체 및 이의 사용 방법
EP4714981A1 (en) Immune effector cell and use thereof
US20260078163A1 (en) T-cell receptor that targets egfr mutation and methods of using the same
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
EA041322B1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car)